Skip to main content
Livermore
Livermore
ZHEN

Captrust Financial Advisors

SEC CIK
0001512024
Latest filing
Aug 13, 2026

TGTX holding history

TG Therapeutics, Inc. in every 13F filed by Captrust Financial Advisors, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TGTX overviewAll 13F holders of TGTXFull Q2 2026 holdings

Shares (Q2 2026)
11,003
Value
$604.5K
% of portfolio
<0.1%
Quarters held
21
Since Q1 2021
Holdings of TGTX by Captrust Financial Advisors, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202611,003$604.5K<0.1%+3,735+51.4%AddedHolders
Q1 20267,268$241.4K<0.1%+493+7.3%AddedHolders
Q4 20256,775$202.0K<0.1%+6,775NewHolders
Q3 20250$00.0%−5,734−100.0%Sold outHolders
Q2 20255,734$206.4K<0.1%−838−12.8%ReducedHolders
Q1 20256,572$259.1K<0.1%−990−13.1%ReducedHolders
Q4 20247,562$227.6K<0.1%−22,765−75.1%ReducedHolders
Q3 202430,327$709.3K<0.1%+5,279+21.1%AddedHolders
Q2 202425,048$445.6K<0.1%+351+1.4%AddedHolders
Q1 202424,697$375.6K<0.1%−5,651−18.6%ReducedHolders
Q4 202330,348$518.3K<0.1%+5,588+22.6%AddedHolders
Q3 202324,760$207.0K<0.1%−1,782−6.7%ReducedHolders
Q2 202326,542$659.3K<0.1%+629+2.4%AddedHolders
Q1 202325,913$389.7K<0.1%+2,854+12.4%AddedHolders
Q4 202223,059$272.8K<0.1%+194+0.8%AddedHolders
Q3 202222,865$135.0K<0.1%+22,600+8,528.3%AddedHolders
Q2 2022265$1.00K<0.1%−147−35.7%ReducedHolders
Q1 2022412$4.00K<0.1%+312+312.0%AddedHolders
Q4 2021100$2.00K<0.1%−11−9.9%ReducedHolders
Q3 2021111$4.00K<0.1%−8−6.7%ReducedHolders
Q2 2021119$5.00K<0.1%−6−4.8%ReducedHolders
Q1 2021125$6.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.